202 related articles for article (PubMed ID: 28969629)
41. What do patients with brain metastases from non-small cell lung cancer want from their treatment?
Dorman S; Hayes J; Pease N
Palliat Med; 2009 Oct; 23(7):594-600. PubMed ID: 19443522
[TBL] [Abstract][Full Text] [Related]
42. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
[TBL] [Abstract][Full Text] [Related]
43. Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer.
Leighl NB; Shepherd FA; Zawisza D; Burkes RL; Feld R; Waldron J; Sun A; Payne D; Bezjak A; Tattersall MH
Br J Cancer; 2008 Jun; 98(11):1769-73. PubMed ID: 18506180
[TBL] [Abstract][Full Text] [Related]
44. Establishment and Validation of Nomogram Model Integrated With Inflammation-Based Factors for the Prognosis of Advanced Non-Small Cell Lung Cancer.
Huang Z; Xing S; Zhu Y; Qu Y; Jiang L; Sheng J; Wang Q; Xu S; Xue N
Technol Cancer Res Treat; 2020; 19():1533033820971605. PubMed ID: 33191854
[TBL] [Abstract][Full Text] [Related]
45. Palliative Care in Lung Cancer: When to Start.
Bhattacharya P; Dessain SK; Evans TL
Curr Oncol Rep; 2018 Nov; 20(11):90. PubMed ID: 30414010
[TBL] [Abstract][Full Text] [Related]
46. Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases.
Kwint M; Walraven I; Burgers S; Hartemink K; Klomp H; Knegjens J; Verheij M; Belderbos J
Lung Cancer; 2017 Oct; 112():134-139. PubMed ID: 29191586
[TBL] [Abstract][Full Text] [Related]
47. A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer.
Xu YH; Lu S
Eur J Surg Oncol; 2014 Mar; 40(3):311-7. PubMed ID: 24332948
[TBL] [Abstract][Full Text] [Related]
48. Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline.
Moeller B; Balagamwala EH; Chen A; Creach KM; Giaccone G; Koshy M; Zaky S; Rodrigues G
Pract Radiat Oncol; 2018; 8(4):245-250. PubMed ID: 29625898
[TBL] [Abstract][Full Text] [Related]
49. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
50. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
Horn L; Bauml J; Forde PM; Davis KL; Myall NJ; Sasane M; Dalal A; Culver K; Wozniak AJ; Baik CS; Mutebi A; Zhang P; Wakelee HA; Johnson BE
Lung Cancer; 2019 Feb; 128():74-90. PubMed ID: 30642457
[TBL] [Abstract][Full Text] [Related]
51. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
[TBL] [Abstract][Full Text] [Related]
52. Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer.
Kim HJ; Kim YJ; Seo MD; Yi HG; Lee SH; Lee SM; Kim DW; Yang SC; Lee CT; Lee JS; Kim YW; Heo DS
Lung Cancer; 2009 Aug; 65(2):242-6. PubMed ID: 19147252
[TBL] [Abstract][Full Text] [Related]
53. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
Ding H; Xin W; Tong Y; Sun J; Xu G; Ye Z; Rao Y
PLoS One; 2020; 15(9):e0238536. PubMed ID: 32877435
[TBL] [Abstract][Full Text] [Related]
54. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
Yang YJ; Park JC; Kim HK; Kang JH; Park SY
Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
[TBL] [Abstract][Full Text] [Related]
55. Construction and validation of prognostic nomograms for elderly patients with metastatic non-small cell lung cancer.
Sun H; Liu M; Yang X; Ren Y; Dai H; Wang C
Clin Respir J; 2022 May; 16(5):380-393. PubMed ID: 35514033
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
[TBL] [Abstract][Full Text] [Related]
57. Palliative care and psychosocial care in metastatic non-small cell lung cancer: factors affecting utilisation of services and impact on patient survival.
Duggan KJ; Wiltshire J; Strutt R; Boxer MM; Berthelsen A; Descallar J; Vinod SK
Support Care Cancer; 2019 Mar; 27(3):911-919. PubMed ID: 30066201
[TBL] [Abstract][Full Text] [Related]
58. The International Atomic Energy Agency (IAEA) randomized trial of palliative treatment of incurable locally advanced non small cell lung cancer (NSCLC) using radiotherapy (RT) and chemotherapy (CHT) in limited resource setting.
Jeremic B; Fidarova E; Sharma V; Faheem M; Ameira AA; Nasr Ben Ammar C; Frobe A; Lau F; Brincat S; Jones G
Radiother Oncol; 2015 Jul; 116(1):21-6. PubMed ID: 26163093
[TBL] [Abstract][Full Text] [Related]
59. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
Xu YP; Li B; Xu XL; Mao WM
Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
[TBL] [Abstract][Full Text] [Related]
60. Prediction of risk of recurrence of venous thromboembolism following treatment for a first unprovoked venous thromboembolism: systematic review, prognostic model and clinical decision rule, and economic evaluation.
Ensor J; Riley RD; Jowett S; Monahan M; Snell KIe; Bayliss S; Moore D; Fitzmaurice D;
Health Technol Assess; 2016 Feb; 20(12):i-xxxiii, 1-190. PubMed ID: 26879848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
